Genitourinary Cancers | Specialty

Treatment Landscape of Advanced Clear Cell RCC

March 31st 2020

Biology of Clear Cell Renal Cell Carcinoma

March 31st 2020

Cabozantinib Combos Show Potential in Ongoing Advanced RCC Trials

March 30th 2020

Bradley McGregor, MD, discusses the CheckMate-9ER trial in metastatic renal cell carcinoma, as well as the need for future studies in histologies beyond clear cell renal cell carcinoma.

IO/Targeted Combos Poised to Enter Metastatic Urothelial Carcinoma Paradigm

March 26th 2020

Daniel P. Petrylak, MD, discusses the current treatment landscape of metastatic urothelial carcinoma and exciting strategies in the pipeline.

FDA Grants IPI-549 Fast Track Designation in Urothelial Carcinoma

March 25th 2020

The FDA has granted a Fast Track Designation to IPI-549 for use in combination with nivolumab for the treatment of patients with advanced urothelial cancer, according to Infinity Pharmaceuticals, Inc., the manufacturer of the PI3K-gamma inhibitor.

Dr. Drakaki on the Design of the MORPHEUS-mUC Trial in Urothelial Carcinoma

March 25th 2020

Alexandra Drakaki, MD, discusses the design of the MORPHEUS-mUC trial in advanced/metastatic urothelial carcinoma.

Expert Highlights Shifting Management of Localized Bladder Cancer

March 19th 2020

John P. Sfakianos, MD, discusses some of the optimal and evolving management strategies in localized bladder cancer.

Improvements Needed for Adjuvant Therapy in RCC

March 18th 2020

Che-Kai Tsao, MD, discusses the current unmet needs in adjuvant therapy for patients with renal cell carcinoma and how current research is addressing such challenges.

Immunotherapy Combinations Are King in Frontline RCC Treatment

March 14th 2020

In metastatic renal cell carcinoma, the use of frontline combination immunotherapy regimens has led to significant survival benefits for patients, and efforts are now being focused on exploring novel options for those who become refractory to this approach.

More Research Required to Define Role of Cytoreductive Nephrectomy in RCC

March 13th 2020

Reza Mehrazin, MD, discusses the need for more research before determining the role of cytoreductive nephrectomy in an era of immunotherapy and targeted therapy.

Dr. Petrylak on Available Treatment Options in Metastatic Bladder Cancer

March 13th 2020

Daniel P. Petrylak, MD, discusses available treatment options in metastatic bladder cancer.

NICE Rejects Pembrolizumab for Urothelial Carcinoma

March 13th 2020

The United Kingdom’s National Institute for Health and Care Excellence has chosen not to recommend pembrolizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-containing chemotherapy.

Dr. Choueiri on Safety Profile of MK-6482 in Advanced Clear Cell RCC

March 12th 2020

Toni K. Choueiri, MD, discusses the safety profile of the oral HIF-2α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

TKI/Immunotherapy Combos Lead Advances in mRCC, But Questions Remain

March 11th 2020

Chung-Han (Joe) Lee, MD, PhD, discussed advancements in metastatic renal cell carcinoma regarding combination regimens and ongoing questions of how to treat patients upon disease progression.

Dr. Tsao on Rationale for Staging Renal Cell Carcinoma

March 10th 2020

Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.

Adjuvant Chemotherapy Shows Strong Benefit in Upper Tract Urothelial Carcinoma

March 7th 2020

Adjuvant platinum-based chemotherapy reduced the risk of disease recurrence or death by 55% in patients with upper tract urothelial carcinoma, according to findings from the phase III POUT trial that have now been published in The Lancet.

Durvalumab/Tremelimumab Combo Misses OS Endpoints in Metastatic Bladder Cancer

March 6th 2020

Durvalumab alone did not improve overall survival compared with standard-of-care chemotherapy in patients with unresectable urothelial cancer whose tumors had high levels (≥25%) of PD-L1 expression, missing both primary endpoints of the phase III DANUBE trial.

Dr. McDermott on VEGF/PD-1 Inhibition in RCC

March 5th 2020

David F. McDermott, MD, discusses the research behind combining VEGF inhibitors with PD-1/PD-L1 inhibitors in renal cell carcinoma treatment.

Rapid Advances Change the Paradigm in Bladder Cancer

March 4th 2020

Arjun V. Balar, MD, discusses how immunotherapy options are helping to reduce reliance on platinum chemotherapy and cystectomy, as well as further efforts to engage the immune system in the fight against bladder cancer and other pathways toward greater treatment efficacy and quality of life for patients.

Dr. Lee on Treatment Options mRCC

March 4th 2020

Chung-Han Lee, MD, PhD, discusses treatment options for patients with metastatic renal cell carcinoma.